Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF

Overview of attention for article published in JACC: Heart Failure, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

news: 1 news outlet
twitter: 31 X users
patent: 1 patent

wikipedia: 1 Wikipedia page
podcasts: 1 podcast

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 34 X posts from 31 X users, with an upper bound of 361,366 followers.

RT @JACCJournals: Biomarker pathways that were most strongly associated with clinical outcomes were also the ones reduced by AZD4831. These…

Biomarker pathways that were most strongly associated with clinical outcomes were also the ones reduced by AZD4831. These results support the further investigation of #myeloperoxidase inhibition in #HFpEF. https://t.co/UmIaNCwJD8 #JACCHF #SATELLITE #Ca…

RT @HanCardiomd: #Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in #HFpEF 🧪 Strong associations…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 30 additional X posts.